These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 10943319)

  • 21. Development of short non-CpG phosphodiester oligonucleotides as immune stimulatory agents.
    Filion MC; Saha N; Gueddi M; Phillips NC
    Vaccine; 2003 Feb; 21(9-10):983-9. PubMed ID: 12547612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells.
    Hartmann G; Battiany J; Poeck H; Wagner M; Kerkmann M; Lubenow N; Rothenfusser S; Endres S
    Eur J Immunol; 2003 Jun; 33(6):1633-41. PubMed ID: 12778481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of CpG oligodeoxynucleotides as immune adjuvants.
    Klinman DM; Currie D; Gursel I; Verthelyi D
    Immunol Rev; 2004 Jun; 199():201-16. PubMed ID: 15233736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant properties of CpG oligonucleotides in primates.
    Verthelyi D
    Methods Mol Med; 2006; 127():139-58. PubMed ID: 16988453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma.
    Sorrentino R; Morello S; Forte G; Montinaro A; De Vita G; Luciano A; Palma G; Arra C; Maiolino P; Adcock IM; Pinto A
    Am J Respir Crit Care Med; 2011 May; 183(10):1369-79. PubMed ID: 21278302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety.
    Klinman DM; Kamstrup S; Verthelyi D; Gursel I; Ishii KJ; Takeshita F; Gursel M
    Springer Semin Immunopathol; 2000; 22(1-2):173-83. PubMed ID: 10944812
    [No Abstract]   [Full Text] [Related]  

  • 27. Oligodeoxynucleotides containing CpG motifs induce low levels of TNF-alpha in human B lymphocytes: possible adjuvants for Th1 responses.
    Bohle B; Orel L; Kraft D; Ebner C
    J Immunol; 2001 Mar; 166(6):3743-8. PubMed ID: 11238615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells.
    Britigan BE; Lewis TS; Waldschmidt M; McCormick ML; Krieg AM
    J Immunol; 2001 Sep; 167(5):2921-8. PubMed ID: 11509640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Specific modification of the immune system with CpG-oligonucleotides].
    Krug A; Hartmann G
    Dtsch Med Wochenschr; 2001 Sep; 126(37):1002-4. PubMed ID: 11555774
    [No Abstract]   [Full Text] [Related]  

  • 30. DNA tumor vaccines.
    Wlazlo AP; Ertl HC
    Arch Immunol Ther Exp (Warsz); 2001; 49(1):1-11. PubMed ID: 11266084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo.
    Dalpke AH; Zimmermann S; Albrecht I; Heeg K
    Immunology; 2002 May; 106(1):102-12. PubMed ID: 11972638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement of anti-tumor effect of plasmid DNA-carrying MUC1 by the adjuvanticity of FLT3L in mouse model.
    Gao FS; Zhan YT; Wang XD; Zhang C
    Immunopharmacol Immunotoxicol; 2018 Aug; 40(4):353-357. PubMed ID: 30111221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells.
    Stunz LL; Lenert P; Peckham D; Yi AK; Haxhinasto S; Chang M; Krieg AM; Ashman RF
    Eur J Immunol; 2002 May; 32(5):1212-22. PubMed ID: 11981808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides.
    Klinman DM; Zeuner R; Yamada H; Gursel M; Currie D; Gursel I
    Ann N Y Acad Sci; 2003 Dec; 1002():112-23. PubMed ID: 14751829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphorothioate oligonucleotides: looking for the motif(s) possessing immunostimulatory activities in humans.
    Brugnolo F; Annunziato F; Sampognaro S; Manuelli C; Cosmi L; Romagnani S; Maggi E; Parronchi P
    Adv Exp Med Biol; 2001; 495():261-4. PubMed ID: 11774576
    [No Abstract]   [Full Text] [Related]  

  • 36. Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine.
    Kojima Y; Xin KQ; Ooki T; Hamajima K; Oikawa T; Shinoda K; Ozaki T; Hoshino Y; Jounai N; Nakazawa M; Klinman D; Okuda K
    Vaccine; 2002 Jul; 20(23-24):2857-65. PubMed ID: 12126895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA vaccine.
    Cui Z
    Adv Genet; 2005; 54():257-89. PubMed ID: 16096015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CpG motifs in bacterial DNA and their immune effects.
    Krieg AM
    Annu Rev Immunol; 2002; 20():709-60. PubMed ID: 11861616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CpG motifs as immune adjuvants.
    Klinman DM; Barnhart KM; Conover J
    Vaccine; 1999 Jan; 17(1):19-25. PubMed ID: 10078603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunostimulatory DNA as adjuvant: efficacy of phosphodiester CpG oligonucleotides is enhanced by 3' sequence modifications.
    Zimmermann S; Heeg K; Dalpke A
    Vaccine; 2003 Feb; 21(9-10):990-5. PubMed ID: 12547613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.